Hybio Pharmaceutical 翰宇药业
16 significant filings since 30 May 2026: 12 on equity incentive, 2 on guarantee or financial assistance and 1 on earnings pre-announcement, and 1 other kind. The latest, on 21 Aug 2026: 关于2026年度向金融机构申请综合授信及担保额度的进展公告. On 11 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 54.67% to 68.42% from the same period a year earlier.
自 30 May 2026 起有 16 份重大公告：equity incentive 12 份、guarantee or financial assistance 2 份、earnings pre-announcement 1 份，另有 1 类。最新一份（21 Aug 2026）：关于2026年度向金融机构申请综合授信及担保额度的进展公告。11 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 54.67% 至 68.42%。
No broker reports from the last twelve months are held for this company. Brokers covered 1,060 of the 2,940 SZSE listings (36%) over the same period. 近十二个月无本公司研报；同期券商覆盖了 2,940 只 SZSE 证券中的 1,060 只（36%）。
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 10 Aug 2018 | 民生证券 | 肖汉山,袁中平 | Buy 买入 | ▼ | Outperform 增持 |
| 27 Jun 2018 | 民生证券 | 肖汉山,袁中平 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。